Multiple Charged and Aromatic Residues in CCR5 Amino-terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein*

CCR5 is a functional receptor for MIP-1α, MIP-1β, RANTES (regulated on activation normal T cell expressed), MCP-2, and MCP-4 and constitutes the main coreceptor for macrophage tropic human and simian immunodeficiency viruses. By using CCR5-CCR2b chimeras, we have shown previously that the second extracellular loop of CCR5 is the major determinant for chemokine binding specificity, whereas the amino-terminal domain plays a major role for human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus coreceptor function. In the present work, by using a panel of truncation and alanine-scanning mutants, we investigated the role of specific residues in the CCR5 amino-terminal domain for chemokine binding, functional response to chemokines, HIV-1 gp120 binding, and coreceptor function. Truncation of the amino-terminal domain resulted in a progressive decrease of the binding affinity for chemokines, which correlated with a similar drop in functional responsiveness. Mutants lacking residues 2–13 exhibited fairly weak responses to high concentrations (500 nm) of RANTES or MIP-1β. Truncated mutants also exhibited a reduction in the binding affinity for R5 Env proteins and coreceptor activity. Deletion of 4 or 12 residues resulted in a 50 or 80% decrease in coreceptor function, respectively. Alanine-scanning mutagenesis identified several charged and aromatic residues (Asp-2, Tyr-3, Tyr-10, Asp-11, and Glu-18) that played an important role in both chemokine and Env high affinity binding. The overlapping binding site of chemokines and gp120 on the CCR5 amino terminus, as well as the involvement of these residues in the epitopes of monoclonal antibodies, suggests that these regions are particularly exposed at the receptor surface.

[1]  K. Arai,et al.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat , 1988, Molecular and cellular biology.

[2]  R. Mark,et al.  Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity. , 1992, The Journal of biological chemistry.

[3]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[4]  C. Hébert,et al.  Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction. , 1994, The Journal of biological chemistry.

[5]  R. Connor,et al.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.

[6]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[7]  Marc Parmentier,et al.  Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.

[8]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[9]  M. Goldsmith,et al.  Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.

[10]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[11]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[12]  I. Charo,et al.  The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. , 1996, The Journal of biological chemistry.

[13]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[14]  G Vassart,et al.  Molecular cloning and functional expression of a new human CC-chemokine receptor gene. , 1996, Biochemistry.

[15]  Jennifer C. Lee,et al.  CXC Chemokines Bind to Unique Sets of Selectivity Determinants That Can Function Independently and Are Broadly Distributed on Multiple Domains of Human Interleukin-8 Receptor B , 1996, The Journal of Biological Chemistry.

[16]  R. Doms,et al.  Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Katlama,et al.  HIV-1 infection in an individual homozygous for CCR5▵32 , 1997, The Lancet.

[18]  J J Goedert,et al.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.

[19]  H. Sheppard,et al.  The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression , 1997, Nature Medicine.

[20]  R. Doms,et al.  Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1 , 1997, Journal of virology.

[21]  Nancy Sullivan,et al.  CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.

[22]  C. Mackay,et al.  Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.

[23]  J. Sodroski,et al.  CD4-independent binding of SIV gp120 to rhesus CCR5. , 1997, Science.

[24]  J. Sodroski,et al.  CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia , 1997, Nature.

[25]  S. Rees,et al.  A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. , 1997, Analytical biochemistry.

[26]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[27]  B. Cullen,et al.  HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.

[28]  R. Doms,et al.  Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. , 1997, Virology.

[29]  R. Doms,et al.  Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry. , 1997, Methods in enzymology.

[30]  J. Mascola,et al.  The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression , 1997, Nature Medicine.

[31]  R. Doms,et al.  CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Marc Parmentier,et al.  The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.

[33]  B. Bennetts,et al.  HIV-1 infection in an individual homozygous for the CCR5 deletion allele , 1997, Nature Medicine.

[34]  E. Fenyö,et al.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.

[35]  I. Charo,et al.  The Amino-terminal Domain of CCR2 Is Both Necessary and Sufficient for High Affinity Binding of Monocyte Chemoattractant Protein 1 , 1997, The Journal of Biological Chemistry.

[36]  P. Murphy,et al.  Determinants of HIV-1 Coreceptor Function on CC Chemokine Receptor 3 , 1997, The Journal of Biological Chemistry.

[37]  J. Sodroski,et al.  CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. , 1998, Cellular immunology.

[38]  J. Westwick,et al.  Chemokines: understanding their role in T-lymphocyte biology. , 1998, The Biochemical journal.

[39]  D. Kwon,et al.  The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. , 1998, Virology.

[40]  J. Grivel,et al.  Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines. , 1998, The Journal of clinical investigation.

[41]  M. Wainberg,et al.  Effect of HIV constructs containing protease‐reverse transcriptase fusion proteins on viral replication , 1998, AIDS.

[42]  S. Kunkel,et al.  Novel roles for chemokines and fibroblasts in interstitial fibrosis. , 1998, Kidney international.

[43]  W. Gong,et al.  Monocyte Chemotactic Protein-2 Activates CCR5 and Blocks CD4/CCR5-mediated HIV-1 Entry/Replication* , 1998, The Journal of Biological Chemistry.

[44]  M. Baggiolini Chemokines and leukocyte traffic , 1998, Nature.

[45]  R. Terkeltaub,et al.  Chemokines and atherosclerosis. , 1998, Current opinion in lipidology.

[46]  R. Strieter,et al.  Tumor angiogenesis is regulated by CXC chemokines. , 1998, The Journal of laboratory and clinical medicine.

[47]  J. Sodroski,et al.  A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5 , 1998, Journal of Virology.

[48]  S. O’Brien,et al.  Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Δ32 , 1998, Journal of Virology.

[49]  Bryan R. Cullen,et al.  Multiple Residues Contribute to the Inability of Murine CCR-5 To Function as a Coreceptor for Macrophage-Tropic Human Immunodeficiency Virus Type 1 Isolates , 1998, Journal of Virology.

[50]  John P. Moore,et al.  Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[51]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[52]  C. Power,et al.  Definition, function and pathophysiological significance of chemokine receptors. , 1998, Trends in pharmacological sciences.

[53]  D. Littman Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.

[54]  William C. Olson,et al.  Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry , 1998, Journal of Virology.

[55]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[56]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[57]  Joseph Sodroski,et al.  Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry , 1999, Cell.

[58]  R. Doms,et al.  CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. , 1999 .

[59]  R. Maki,et al.  Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. , 1999, Trends in pharmacological sciences.

[60]  D. Weissman,et al.  Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[61]  D. Littman,et al.  Fusion-competent vaccines: broad neutralization of primary isolates of HIV. , 1999, Science.

[62]  R. Doms,et al.  HIV and SIV gp120 binding does not predict coreceptor function. , 1999, Virology.

[63]  N. Skelton,et al.  Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. , 1999, Structure.

[64]  M. Essex,et al.  Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[66]  R. Doms,et al.  Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains , 1999, Journal of Virology.